Champions Oncology, Inc. announced significant advancements in its bioanalytical services portfolio on January 8, 2025. The company integrated multiple global Cytek Aurora flow cytometers, enhancing its spectral and conventional flow cytometry capabilities.
This technological upgrade is designed to elevate Champions Oncology's service offerings within its clinical bioanalytical services. The investment in advanced instrumentation aims to provide more comprehensive and competitive solutions for its clients.
Additionally, Troy Tremaine, MBA, was appointed to spearhead the Bioanalytical Commercial Strategy. This new leadership is expected to drive the commercial expansion and strategic development of the enhanced bioanalytical services portfolio, reinforcing the company's position in oncology research.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.